Opinion

Video

Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024

Dr Garfall, MD, provides insights following results derived from the MajesTEC-1 study.

Video content above is prompted by the following:

  • Discuss the data you presented at the 2024 ASCO Annual Meeting on long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM).
    • What was the objective of this study?
    • How was this study designed/what methodology was used?
    • What results were presented?
Related Videos
This series features 1 KOL.
A panel of 4 experts on chronic spontaneous urticaria
A panel of 4 experts on chronic spontaneous urticaria
1 KOL is featured in this series.
Related Content
CH LogoCenter for Biosimilars Logo